+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Radiopharmaceuticals - Global Market Trajectory & Analytics

  • ID: 835008
  • Report
  • May 2021
  • Region: Global
  • 590 Pages
  • Global Industry Analysts, Inc
New Therapeutic Radiopharmaceuticals to Drive Global Market

FEATURED COMPANIES

  • Alliance Medical
  • Avid Radiopharmaceuticals
  • Cardinal Health, Inc.
  • Immunomedics, Inc.
  • Jubilant Pharma
  • Nordion, Inc.

Global Radiopharmaceuticals Market to Reach US$9.9 Billion by the Year 2027


Amid the COVID-19 crisis, the global market for Radiopharmaceuticals estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at a CAGR of 9.4% over the analysis period 2020-2027.SPECT Radioisotopes, one of the segments analyzed in the report, is projected to grow at a 9.3% CAGR to reach US$4.4 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PET Radioisotopes segment is readjusted to a revised 9.5% CAGR for the next 7-year period. This segment currently accounts for a 24% share of the global Radiopharmaceuticals market.

The U.S. Accounts for Over 47.7% of Global Market Size in 2020, While China is Forecast to Grow at a 12.7% CAGR for the Period of 2020-2027


The Radiopharmaceuticals market in the U.S. is estimated at US$2.5 Billion in the year 2020. The country currently accounts for a 47.74% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$645.7 Million in the year 2027 trailing a CAGR of 12.7% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR while Rest of European market (as defined in the study) will reach US$645.7 Million by the year 2027.

Beta Emitters Segment Corners a 16.5% Share in 2020


In the global Beta Emitters segment, USA, Canada, Japan, China and Europe will drive the 10.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$773.7 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$481.1 Million by the year 2027, while Latin America will expand at a 11.3% CAGR through the analysis period.

Select Competitors (Total 78 Featured) -

  • Actinium Pharmaceuticals, Inc.
  • Alliance Medical
  • Alseres Pharmaceuticals, Inc.
  • Avid Radiopharmaceuticals
  • Avid Bioservices Inc
  • Bayer HealthCare Pharmaceuticals
  • Bracco Diagnostics, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Ion Beam Applications S.A
  • Immunomedics, Inc.
  • Jubilant Pharma
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd
  • Nordion, Inc.
  • Novartis/Advanced Accelerator Applications
  • PETNET Solutions Inc.
  • Positron Corporation
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alliance Medical
  • Avid Radiopharmaceuticals
  • Cardinal Health, Inc.
  • Immunomedics, Inc.
  • Jubilant Pharma
  • Nordion, Inc.
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • COVID-19-Led Disruptions Exhaust Radiopharmaceuticals Supply to Hinder Nuclear Medicine Procedures in Most Countries
  • Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in U.S Hospitals
  • Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals Struggling with Seamless Supply of Medical Radioisotopes
  • Nuclear Medicine Services Limp Back to Normality after Easing of COVID-19 Restrictions
  • COVID-19 Presents Generational Opportunity
  • Radiopharmaceuticals: A Prelude
  • Mechanism of Action
  • Global Supply Shortages Continue to Challenge Market Growth
  • Exhibit 1: A Glimpse at Mo-99 Processors Worldwide
  • Exhibit 2: Nuclear Research Reactor Irradiators Worldwide: A Snapshot
  • Outlook
  • Key Market Drivers
  • Market Restraints
  • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
  • Classification of Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals: The Dominant Segment
  • Key Drivers
  • Positron Emission Tomography (PET)
  • Major PET Isotopes and their Applications
  • Single Photon Emission Computed Tomography (SPECT)
  • Major Isotopes and their Diagnostic Applications
  • Therapeutic Radiopharmaceuticals
  • Select Isotopes and their Therapeutic Applications
  • Key Drivers
  • Competitive Landscape
  • Exhibit 3: Radiopharmaceuticals Competitor Market Share Scenario Worldwide (in %): 2019
  • Recent Industry Activity
  • World Brands
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
  • Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals
  • Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications
  • Advent of New Radiopharmaceuticals Widen Scope
  • Select New Products
  • Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
  • Select Commercially Available Therapeutic Radiopharmaceuticals
  • PET Eclipses SPECT in Cardiovascular Imaging
  • Exhibit 4: Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2019
  • Cardiac Amyloidosis Visualization: A Potential Application for PET
  • Innovative Radiopharmaceuticals to Boost Cardiac Applications
  • Exhibit 5: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Application of PET in Drug Development to Expand Opportunities
  • Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
  • Personalized Medicine Drives Nuclear Medicine
  • XHIBIT: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
  • Exhibit 6: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
  • Rise in Incidence of Neurological Disorders to Drive Growth
  • Rising Cancer Incidence Worldwide Spurs Demand
  • Exhibit 7: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Exhibit 8: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • Exhibit 9: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • Ageing Population: A Vital Demography
  • Exhibit 10: Global Aging Population: Population of 65+ Individuals (in Thousands) by Region for 2019 and 2030
  • Exhibit 11: Global Cancer Deaths by Age Group (in %) for 2019
  • Rise in Healthcare Expenditure to Drive Growth
  • Exhibit 12: Elderly Healthcare Expenditure as a % of GDP
  • Exhibit 11: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Relevant Aspects of Radiopharmaceutical Production
  • Regulatory Regime Governing Production and Use of Radiopharmaceuticals
4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

UNITED STATES
  • Market Overview
  • Diagnostic Applications Stimulate Future Growth
  • Demographic Changes Offer Growth Opportunities
  • Exhibit 13: US Elderly Population: Expected Growth Rates Over the Years 2005-2025
  • Rising Incidence of Cancer: A Major Growth Driver
  • Exhibit 14: Leading Sites of New Cancer Cases in Males: 2020
  • Exhibit 15: Leading Sites of New Cancer Cases in Females: 2020
  • Cardiovascular Imaging to Lead Volume Growth
  • Radiopharmaceuticals Usage Strengthens in PET Imaging
  • Radioisotope/Radiopharmaceuticals Supply Scenario
  • Passing of Medicare Diagnostic Radiopharmaceutical Payment Equity Act
CANADA
  • Market Overview
  • Efforts on to Address Mo-99 Supply Shortage
JAPAN
  • Market Overview
CHINA
  • Market Overview
EUROPE
  • Market Overview
FRANCE

GERMANY

ITALY

UNITED KINGDOM

SPAIN

RUSSIA

REST OF EUROPE

ASIA-PACIFIC
  • Market Overview
AUSTRALIA

INDIA
  • Market Overview
SOUTH KOREA

REST OF ASIA-PACIFIC

LATIN AMERICA

ARGENTINA

BRAZIL

MEXICO

REST OF LATIN AMERICA

MIDDLE EAST

IRAN

ISRAEL

SAUDI ARABIA

UNITED ARAB EMIRATES

REST OF MIDDLE EAST

AFRICA

IV. COMPETITION
  • Total Companies Profiled: 77
Note: Product cover images may vary from those shown
  • Actinium Pharmaceuticals, Inc.
  • Alliance Medical
  • Alseres Pharmaceuticals, Inc.
  • Avid Radiopharmaceuticals
  • Avid Bioservices Inc
  • Bayer HealthCare Pharmaceuticals
  • Bracco Diagnostics, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Ion Beam Applications S.A
  • Immunomedics, Inc.
  • Jubilant Pharma
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd
  • Nordion, Inc.
  • Novartis/Advanced Accelerator Applications
  • PETNET Solutions Inc.
  • Positron Corporation
Note: Product cover images may vary from those shown
Adroll
adroll